

Table S1

*Demographic, Clinical, and Medication Characteristics Among Patients Treated with Cognitive Enhancement Therapy or Enriched Supportive Therapy.*

Variable	CET		EST		<i>p</i> <sup>a</sup>
	(N = 30)		(N = 23)		
	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>	
<b>Demographics</b>					
Age	25.99	6.54	26.42	6.60	.812
Male (N / %)	19	63%	16	70%	.855
Caucasian (N / %)	20	67%	16	70%	.656
Attended College (N / %)	22	73%	17	74%	.790
Not Employed (N / %)	22	73%	16	70%	.995
Schizophrenia (N / %)	20	67%	15	65%	.855
Years Since First Psychotic Symptom	3.17	2.32	3.28	2.08	.854
IQ	97.90	7.74	98.83	10.24	.709
<b>Symptoms</b>					
BPRS Total	39.47	9.21	40.09	11.03	.824
Wing Negative Symptoms Scale	18.30	4.19	18.65	3.32	.742
Raskin Depression Scale	6.60	2.63	6.35	2.01	.705
Covi Anxiety Scale	5.67	1.88	6.13	2.22	.415
<b>Treatment Exposure/Adherence<sup>b</sup></b>					
Total Hours of Treatment	162.27	43.40	46.04	18.78	< .001
% Sessions Missed	11.29	6.97	15.54	15.85	.233
<b>Medications</b>					
Dose (baseline, cpz)	412.22	343.58	417.61	309.85	.953
Dose (year 1, cpz)	402.33	332.93	482.78	345.16	.426
Dose (year 2, cpz)	473.58	384.43	514.30	396.01	.735
Using Atypical Agent (baseline, N / %)	30	100%	22	96%	.893
Using Atypical Agent (year 1, N / %)	25	100%	21	100%	.555
Using Atypical Agent (year 2, N / %)	24	100%	19	100%	.446
Compliant (baseline, N / %)	27	90%	20	87%	.928
Compliant (year 1, N / %)	25	100%	17	81%	.079
Compliant (year 2, N / %)	22	92%	16	84%	.781

*Note.* CET = Cognitive Enhancement Therapy, BPRS = Brief Psychiatric Rating Scale, EST = Enriched Supportive Therapy.

<sup>a</sup> $\chi^2$  test or independent *t*-test, two-tailed, for significant differences between CET and EST participants.

Table S2

*Voxel-Based Morphometric Analyses of Gray Matter Density Change in a Two-Year Trial of Cognitive Enhancement Therapy or Enriched Supportive Therapy Restricted to Only Cases With Follow-up Data (N = 44).*

MNI Coordinates (x, y, z)	Cluster Size	Location	BA	z	p	Direction
Main Effect of Time						
-4, -66, -12	2925	Bilateral cerebellum, left culmen	NA	5.67	< .001	Loss
-2, -32, 34	547	Left medial and posterior cingulate	23/31	3.83	< .001	Loss
Treatment x Time Interaction						
-26, -42, -6	805	Left parahippocampal gyrus, left fusiform gyrus, left hippocampus	35/36/37	4.90	< .001	EST loss > CET loss
-14, -2, -24	471	Left parahippocampal gyrus, left amygdala	28/34/38	3.49	< .001	EST loss > CET loss
8, 40, 16	348	Bilateral anterior cingulate	9/10/32	3.47	< .001	EST loss > CET loss
46, 0, -6	267	Right insula	22/38	3.56	< .001	EST loss > CET loss

*Note.* BA = Brodmann's Area, CET = Cognitive Enhancement Therapy, EST = Enriched Supportive Therapy

Table S3

*Changes in Gray Matter Volume During Two Years of Cognitive Enhancement Therapy or Enriched Supportive Therapy Restricted to Only Cases With Follow-up Data.*

Site/Cluster	CET (N = 25)			EST (N = 19)			Between-Group Effect		
	Baseline	Year 1	Year 2	Baseline	Year 1	Year 2	t	p	p <sup>a</sup>
	M (SD)	M (SD)	M (SD)	M (SD)	M (SD)	M (SD)			
<b>Frontal</b>									
Anterior Cingulate (L)	5.84 (.81)	5.87 (.82)	5.90 (.88)	6.02 (1.07)	5.97 (1.17)	5.92 (.89)	1.23	.223	.223
Anterior Cingulate (R)	5.11 (.70)	5.07 (.71)	5.03 (.74)	5.28 (.93)	5.16 (1.00)	5.03 (.74)	1.73	.088	.176
<b>Medial temporal</b>									
Amygdala (L)	1.06 (.13)	1.08 (.11)	1.09 (.12)	1.05 (.15)	1.05 (.15)	1.04 (.12)	2.35	.022	.039
Fusiform Gyrus (L)	9.87 (1.03)	9.95 (1.00)	10.03 (1.08)	9.89 (1.49)	9.82 (1.37)	9.74 (1.18)	2.25	.028	.039
Hippocampus (L)	3.98 (.34)	3.98 (.33)	3.99 (.35)	4.04 (.50)	3.98 (.50)	3.92 (.46)	2.31	.024	.039
ParaHippocampal Gyrus (L)	3.83 (.39)	3.85 (.38)	3.87 (.43)	3.81 (.52)	3.78 (.49)	3.74 (.36)	2.10	.039	.039
<b>Temporal</b>									
Insula (R)	7.81 (.90)	7.88 (.93)	7.96 (.99)	7.65 (1.19)	7.60 (1.30)	7.55 (.94)	1.82	.074	-

*Note.* All volumetric data are presented in cubic centimeters.

CET = Cognitive Enhancement Therapy, EST = Enriched Supportive Therapy

<sup>a</sup>p-values are adjusted for multiple inference testing within each cluster of results using Hochberg's correction